Acuta Capital Partners as of March 31, 2017
Portfolio Holdings for Acuta Capital Partners
Acuta Capital Partners holds 54 positions in its portfolio as reported in the March 2017 quarterly 13F filing
Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
---|---|---|---|---|---|
SPDR S&P Biotech (XBI) | 12.0 | $51M | 730k | 69.34 | |
iShares Russell 2000 Index (IWM) | 9.4 | $40M | 290k | 137.48 | |
Assembly Biosciences | 7.9 | $33M | 1.3M | 25.49 | |
Veracyte (VCYT) | 7.0 | $30M | 3.2M | 9.18 | |
ACADIA Pharmaceuticals (ACAD) | 6.4 | $27M | 783k | 34.38 | |
Lion Biotechnologies | 6.1 | $26M | 3.5M | 7.45 | |
IRIDEX Corporation (IRIX) | 4.8 | $20M | 1.7M | 11.87 | |
Neuroderm Ltd F | 3.8 | $16M | 600k | 26.55 | |
Ascendis Pharma A S (ASND) | 3.6 | $15M | 550k | 28.00 | |
Edge Therapeutics | 2.9 | $12M | 1.4M | 9.11 | |
BioCryst Pharmaceuticals (BCRX) | 2.5 | $11M | 1.2M | 8.40 | |
WebMD Health | 2.4 | $10M | 190k | 52.68 | |
Nabriva Therapeutics | 1.9 | $8.1M | 678k | 12.00 | |
Marvell Technology Group | 1.8 | $7.6M | 498k | 15.26 | |
Viveve Med | 1.7 | $7.2M | 1.1M | 6.33 | |
CAS Medical Systems | 1.5 | $6.4M | 4.4M | 1.45 | |
Chembio Diagnostics | 1.5 | $6.4M | 1.2M | 5.30 | |
Dbv Technologies S A | 1.5 | $6.3M | 180k | 35.22 | |
Oxford Immunotec Global | 1.4 | $6.0M | 386k | 15.49 | |
Aclaris Therapeutics (ACRS) | 1.4 | $6.0M | 200k | 29.82 | |
Zogenix | 1.4 | $5.8M | 537k | 10.85 | |
Tesaro | 1.3 | $5.4M | 35k | 153.86 | |
Ra Pharmaceuticals | 1.2 | $5.3M | 248k | 21.29 | |
Evolent Health (EVH) | 1.2 | $5.1M | 230k | 22.30 | |
Johnson & Johnson (JNJ) | 1.2 | $5.0M | 40k | 124.55 | |
Viewray (VRAYQ) | 1.1 | $4.6M | 601k | 7.71 | |
Avexis | 1.0 | $4.3M | 56k | 76.04 | |
Anaptysbio Inc Common (ANAB) | 1.0 | $4.1M | 166k | 24.97 | |
Medicines Company | 0.8 | $3.4M | 70k | 48.90 | |
Nanostring Technologies (NSTGQ) | 0.8 | $3.3M | 165k | 19.87 | |
Immunomedics | 0.8 | $3.3M | 503k | 6.47 | |
Aurinia Pharmaceuticals (AUPH) | 0.7 | $2.9M | 400k | 7.34 | |
Clovis Oncology | 0.6 | $2.6M | 40k | 63.68 | |
Corbus Pharmaceuticals Hldgs | 0.6 | $2.4M | 290k | 8.25 | |
Progenics Pharmaceuticals | 0.6 | $2.4M | 250k | 9.44 | |
Essa Pharma | 0.4 | $1.9M | 605k | 3.10 | |
Nektar Therapeutics (NKTR) | 0.4 | $1.8M | 77k | 23.47 | |
Sage Therapeutics (SAGE) | 0.3 | $1.4M | 20k | 71.05 | |
Clearside Biomedical (CLSD) | 0.3 | $1.4M | 175k | 7.94 | |
Alimera Sciences | 0.3 | $1.4M | 974k | 1.40 | |
Syneron Medical Ltd ord | 0.3 | $1.3M | 122k | 10.55 | |
Invitae (NVTAQ) | 0.3 | $1.3M | 120k | 11.06 | |
Xbiotech (XBIT) | 0.3 | $1.3M | 80k | 16.48 | |
Array BioPharma | 0.3 | $1.1M | 121k | 8.94 | |
Versartis | 0.2 | $1.0M | 49k | 21.34 | |
Advisory Board Company | 0.2 | $997k | 21k | 46.81 | |
Rockwell Medical Technologies | 0.2 | $876k | 140k | 6.26 | |
Concert Pharmaceuticals I equity | 0.2 | $837k | 49k | 17.06 | |
Aehr Test Systems (AEHR) | 0.1 | $587k | 122k | 4.81 | |
Omeros Corporation (OMER) | 0.1 | $454k | 30k | 15.13 | |
Quotient | 0.0 | $132k | 19k | 6.98 | |
Oncobiologics | 0.0 | $78k | 29k | 2.68 | |
Oncobiologics Inc *w exp 02/18/201 | 0.0 | $78k | 97k | 0.80 | |
Oncobiologics Inc *w exp 05/18/201 | 0.0 | $48k | 97k | 0.50 |